Bank of America’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Bank of America’s Portfolio NVET Stock Details NVET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-800	Closed	-$5K	–	7513
2017 Q2	$5K	Sell	800 -1,590	-67%	-$10K	﹤0.01%	6625
2017 Q1	$9K	Sell	2,390 -7,000	-75%	-$24.6K	﹤0.01%	6578
2016 Q4	$35K	Sell	9,390 -560	-6%	-$2.31K	﹤0.01%	6090
2016 Q3	$41K	Sell	9,950 -2,190	-18%	-$10.4K	﹤0.01%	5815
2016 Q2	$56K	Sell	12,140 -3,100	-20%	-$10.8K	﹤0.01%	5791
2016 Q1	$50K	Buy	15,240 +390	+3%	+$1.27K	﹤0.01%	5797
2015 Q4	$51K	Sell	14,850 -55,229	-79%	-$218K	﹤0.01%	6037
2015 Q3	$255K	Buy	70,079 +14,228	+25%	+$64.8K	﹤0.01%	5212
2015 Q2	$278K	Buy	55,851 +26,327	+89%	+$182K	﹤0.01%	5079
2015 Q1	$237K	Buy	+29,524	New	+$279K	﹤0.01%	4820

Bank of America's NVET Position: Q3 2017 in Review

Bank of America sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q3 2017, closing a stake of 800 shares — an estimated $5K sold.

Bank of America first reported a position in NVET in Q1 2015 and held it in 10 quarters. The position peaked at $278K in Q2 2015. 0 funds tracked by Wall St. Rank hold NVET as of Q3 2017.

Bank of America reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Bank of America sold 800 Nexvet Biopharma plc Ordinary Shares shares in Q3 2017, an estimated $5K.
Bank of America first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 10 quarters.
Bank of America's Nexvet Biopharma plc Ordinary Shares position peaked at $278K in Q2 2015.
0 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q3 2017.

Based on Bank of America's 13F filing for Q3 2017, filed 14 Nov 2017.